Literature DB >> 6198295

Monoclonal antibody against a cryptic carbohydrate antigen of murine and human lymphocytes. I. Antigen expression in non-cryptic or unsubstituted form on certain murine lymphomas, on a spontaneous murine mammary carcinoma, and on several human adenocarcinomas.

B M Longenecker, A F Rahman, J B Leigh, R A Purser, A H Greenberg, D J Willans, O Keller, P K Petrik, T Y Thay, M R Suresh.   

Abstract

This paper describes an IgM monoclonal antibody (49H.8) which was produced following immunization of BALB/c mice with human neuraminidase-treated erythrocytes (NE-RBC). 49H.8 reacts with NE-RBC, neuraminidase-treated T lymphocytes (NE-T) and NE B lymphocytes of both human and murine origin. Little or no reactivity with untreated T or B cells could be detected. Thus the 49H.8 antigen is "cryptic" in most normal lymphocytes of both humans and mice. In contrast, the 49H.8 antigen was detected in non-cryptic or unsubstituted form on many non-treated murine lymphomas of both B- and T-cell origin, on the spontaneous murine mammary carcinoma, TA3-HA and on several human adenocarcinomas. The 49H.8 antigen appears to be related to the previously described 49H.24 antigen as shown by sugar inhibition experiments. 49H.24 reacts most strongly with the synthetic disaccharide (betaGa1 (I leads to 3)alpha Ga1NAc) but not at all with beta Ga1(I leads to 3)beta Ga1Nac. 49H.24 does not react with any of the murine or human tumors tested. 49H.8 reacts with both the alpha and beta forms of the disaccharide but reacts most strongly with phenyl-beta-galactoside-containing compounds. In contrast, phenyl-alpha-galactoside-containing compounds produced no reaction. The natural determinant detected by this antibody was not determined but various possibilities are considered. 49H.8 was used to detect antigen apparently shed from growing TA3-Ha cells into the serum and ascites of tumor-bearing mice. These observations suggest that the 49H.8 monoclonal antibody will be valuable as a specific reagent for a common tumor-associated antigen shared by certain murine and human tumors, and as a means of assaying shed tumor antigen in circulation as in the TA3-Ha mammary adenocarcinoma model.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198295     DOI: 10.1002/ijc.2910330119

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.

Authors:  C M Henningsson; S Selvaraj; G D MacLean; M R Suresh; A A Noujaim; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 3.  Neoplastic cells as targets of spontaneously cytotoxic lymphocytes: studies with natural killer-like cell lines.

Authors:  A E Lagarde
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

4.  In vivo localization of radioiodinated peanut lectin in a murine TA3/Ha mammary carcinoma model.

Authors:  A Shysh; S M Eu; A A Noujaim; M R Suresh; B M Longenecker
Journal:  Eur J Nucl Med       Date:  1985

5.  Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.

Authors:  S Adluri; F Helling; S Ogata; S Zhang; S H Itzkowitz; K O Lloyd; P O Livingston
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

6.  Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.

Authors:  G D MacLean; M Reddish; R R Koganty; T Wong; S Gandhi; M Smolenski; J Samuel; J M Nabholtz; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Expression of markers shared between human natural killer cells and neuroblastoma lines.

Authors:  R C McGarry; A Pinto; D R Hammersley-Straw; C L Trevenen
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 8.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.